Metabolic syndrome (MS) bladder cancer (BC) grade meta-analysis stage form (available at http://dx.doi.org/10.21037/tcr-20-3350). The authors have no conflicts of interest to declare.

Antibodies Monoclonal/adverse effects/therapeutic use Antibodies Monoclonal Humanized/adverse effects/therapeutic use Antineoplastic Agents Immunological/*therapeutic use B7-H1 Antigen/*antagonists & inhibitors Clinical Trials Phase III as Topic Humans Network Meta-Analysis Programmed Cell Death 1 Receptor/*antagonists & inhibitors Salvage Therapy/*methods Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/*secondary PD-1 inhibitor PDL-1 inhibitor atezolizumab pembrolizumab urothelial bladder cancer

肌层浸润性膀胱癌 保留膀胱的综合治疗 5年生存率 Meta分析

*Genetic Association Studies *Genetic Predisposition to Disease Genotype Glutathione Transferase/*genetics Humans Odds Ratio *Polymorphism Genetic Publication Bias Risk Urinary Bladder Neoplasms/*genetics Bladder cancer Gstm1 Gstp1 Gstt1 Gene polymorphism Meta-analysis PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

bladder tumor childhood exposure environmental smoking nonsmoking adult

bladder cancer meta-analysis system review tumor associated macrophages

经尿道膀胱肿瘤电切术 经尿道前列腺电切术 同期手术 Meta分析 TURBT TURP

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Disease-Free Survival Humans Saline Solution/*administration & dosage/adverse effects *Therapeutic Irrigation/adverse effects Urinary Bladder Neoplasms/*surgery Water/*administration & dosage/adverse effects

前列腺癌 放疗 继发性膀胱癌 前列腺癌根治术

bladder cancer clinicopathological characteristics lncRNA prognosis

β-连环蛋白 膀胱癌 病例-对照研究 Meta分析

Bladder cancer chemotherapy neoadjuvant therapy

*Adaptation Psychological Humans Quality of Life Survivors/*psychology Urinary Bladder Neoplasms/mortality/pathology/*psychology Bladder cancer Cystectomy Diagnosis Patients’ experience Treatment FUNDING: This work was funded by Yorkshire Cancer Research (grant number S388).

Adjuvants Immunologic/*administration & dosage/adverse effects Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects BCG Vaccine Carcinoma in Situ/mortality/pathology/*therapy Combined Modality Therapy/adverse effects/methods Disease Progression Drug Administration Schedule Humans Interferon-alpha/*administration & dosage/adverse effects Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Withholding Treatment/statistics & numerical data

Administration Intravesical BCG Vaccine/administration & dosage/*therapeutic use Chemotherapy Adjuvant Dose-Response Relationship Drug Drug Administration Schedule Humans Neoplasm Recurrence Local Prospective Studies Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/mortality/surgery

Ki-67 bladder cancer meta-analysis prognosis urothelial carcinoma

PSCA 膀胱癌 基因多态性 Meta分析

Aged Blood Loss Surgical Cystectomy/*adverse effects/*methods Female Humans Length of Stay Male Middle Aged Operative Time Postoperative Complications/etiology Quality of Life Randomized Controlled Trials as Topic Robotic Surgical Procedures/*adverse effects/*methods Treatment Outcome Urinary Bladder/*surgery Urinary Bladder Neoplasms/surgery Urinary Diversion/*adverse effects/*methods